Effects of celecoxib on bcr-abl fusion protein in chronic myeloid leukemia primary cells
10.3760/cma.j.issn.1009-9921.2011.01.016
- VernacularTitle:塞来昔布对慢性粒细胞白血病原代细胞bcr-abl融合蛋白的影响
- Author:
Dingsheng LIU
;
Yufeng LI
;
Min LI
;
Banghe DING
;
Jiabin ZHU
;
Zhengmei HE
- Publication Type:Journal Article
- Keywords:
Leukemia,myeloid,chronic;
Celecoxib;
Cyclooxygenase 2 inhibitors;
Fusion proteins,bcr-abl
- From:
Journal of Leukemia & Lymphoma
2011;20(1):49-51
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the effects of celecoxib, a cyclooxygenase-2 (COX-2) specific inhibitor, on the mRNA expression protein expression and protein tyrosine kinase (PTK) activity of bcr-abl fusion gene in chronic myeloid leukemia (CML) primary cells. Methods The primary cells were incubated with various concentration of celecoxib (0, 10, 20, 40, 80, 160 μmol/L) for 36 hours, then the changes of mRNA expression, p210 expression and PTK activity of bcr-abl fusion gene in each group were examined respectively by real time quantitative reverse transcriptase polymerase chain reaction (RQ-RT-PCR), Western blotting and PTK activity analysis. Results The mRNA expression was downregulated with high concentration of celecoxib (80-160 μmol/L), and p210 expression was decreased gradually after increasing celecoxib. The PTK activity was inhibited in a concentration-independent way, and the statistic difference was observed only above 40μmol/L concentration of celecoxib. Conclusion Celecoxib can downregulate mRNA,and the protein expression of bcr-abl fusion gene; and inhibit the PTK activity by defferent extent.
